New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring1 hepatitis C . As part of a compassionate2 use program, 104 post-liver transplant patients with recurring HCV who had exhausted3 all treatment options and had poor clinical prognoses, received sofosbuvir and ribavirin with pegylated interferon included at the physicians discretion4 for up to 48 weeks. Among patients whose clinical outcomes have been reported, 62% achieved SVR12. Additionally, 62% of patients had improvements in clinical conditions associated with hepatic decompensation and/or improvement in liver function tests. SOF+RBVPEG was well-tolerated and led to high rates of virologic（病毒学） suppression.EASLs European Policy Councillor Professor Patrizia Burra of the Multivisceral Transplant Unit, Padova University Hospital, Padua, Italy said: There are currently no effective treatment options for this patient group. However, this new trial involving the nucleotide polymerase inhibitor sofosbuvir has demonstrated promising5 results, providing further evidence of its clinical potential.For patients with advanced hepatitis C liver disease, liver transplants offer a second chance, continued Professor Burra, and for those who continue to suffer post-surgery, its important for us to keep following up all avenues possible to improve their quality of life.Other research revealed at the International Liver CongressTM 2014 showed that most patients with mild hepatitis C recurrence6 diagnosed one year after liver transplant have excellent long-term outcomes.In the second study, 172 patients who were diagnosed with mild hepatitis C recurrence one year after undergoing liver transplant surgery between 1999 and 2012 were followed for six and a half years with all relevant transplant-related, donor7 and recipient8 variables recorded. The cumulative9 probability of HCV-related graft10 loss five and 10 years after liver transplant were 3% and 10%, respectively.However one third of these patients are still at risk of going on to develop cirrhosis, further demonstrating the need for antiviral therapy pre or post-transplant.Hepatitis C infection is a common cause of liver transplantation, with virus-related diseases comprising 40% of primary indications for liver transplantation in Europe among patients with cirrhosis.More than 5,500 liver transplantations are currently performed in Europe per year.
点击收听单词发音
1 recurring adj.往复的，第三发生的 参考例句： This kind of problem is recurring often. 这种问题常常发生。 For our own country, it has been a time for recurring trial. 就大家国家而言，它经过了一个反复考验的时期。
相关文章推荐
